Enzalutamide: Development from bench to bedside

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 6, 2015, Pages 280-288

  Bambury, R M ^a   Scher, H I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

AR targeted therapies; Castration resistant prostate cancer; Enzalutamide; MDV3100; Prostate cancer

Indexed keywords

ABIRATERONE; BICALUTAMIDE; ENZALUTAMIDE; PHENYLTHIOHYDANTOIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; COMPARATIVE EFFECTIVENESS; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE QUALITY; HUMAN; MALE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SEIZURE SUSCEPTIBILITY; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION;

EID: 84929943324     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.12.017     Document Type: Review

References (38)

1. McPhaul M.J. Androgen receptor mutations and androgen insensitivity. Mol Cell Endocrinol 2002, 198:61-67.
2. Huggins C., Hodges C.V. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prosate. Cancer Res 1941, 1:293-297.
3. Huggins C., Stevens R.E., Hodges C.V. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941, 43:209-223.
4. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A.T., et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A 1982, 79:1658-1662.
5. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995, 9:401-406.
6. Taplin M.E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., Ogata G.K., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995, 332:1393-1398.
7. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005, 23:8253-8261.
8. Antonarakis E.S., Lu C., Wang H., Luber B., Nakazawa M., Roeser J.C., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014, 371:1028-1038.
9. Watson P.A., Chen Y.F., Balbas M.D., Wongvipat J., Socci N.D., Viale A., et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010, 107:16759-16765.
10. Locke J.A., Guns E.S., Lehman M.L., Ettinger S., Zoubeidi A., Lubik A., et al. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate 2010, 70:239-251.
11. Yang M., Xie W., Mostaghel E., Nakabayashi M., Werner L., Sun T., et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2011, 29:2565-2573.
12. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
13. Carver B.S., Chapinski C., Wongvipat J., Hieronymus H., Chen Y., Chandarlapaty S., et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011, 19:575-586.
14. Taylor C.D., Elson P., Trump D.L. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993, 11:2167-2172.
15. Prostate Cancer Trialists' Collaborative Group Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000, 355:1491-1498.
16. Joyce R., Fenton M.A., Rode P., Constantine M., Gaynes L., Kolvenbag G., et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998, 159:149-153.
17. Kucuk O., Fisher E., Moinpour C.M., Coleman D., Hussain M.H., Sartor A.O., et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001, 58:53-58.
18. Scher H.I., Liebertz C., Kelly W.K., Mazumdar M., Brett C., Schwartz L., et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997, 15:2928-2938.
19. Kelly W.K., Scher H.I. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993, 149:607-609.
20. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004, 10:33-39.
21. Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
22. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
23. Machiels J.P., Mazzeo F., Clausse M., Filleul B., Marcelis L., Honhon B., et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008, 26:5261-5268.
24. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
25. Scher H.I., Beer T.M., Higano C.S., Anand A., Taplin M.E., Efstathiou E., et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-1446.
26. Scher H.I., Halabi S., Tannock I., Morris M., Sternberg C.N., Carducci M.A., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
27. Scher H.I., Morris M.J., Basch E., Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011, 29:3695-3704.
28. Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
29. Fizazi K., Scher H.I., Miller K., Basch E., Sternberg C.N., Cella D., et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014, 15:1147-1156.
30. Cella D., Nichol M.B., Eton D., Nelson J.B., Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy-Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 2009, 12:124-129.
31. Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y., Sternberg C.N., Higano C.S., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014, 371:424-433.
32. Bambury R.M., Louw J., Krupa R., Danila D., Arslan Z., Schreiber N.A., et al. Characteristics of de novo resistance to androgen targeted therapies through circulating tumors cells analysis in metastatic castration resistant prostate cancer patients. ESMO Congress 2014. Ann Oncol 2014, 25(suppl_4):iv58-iv84.
33. Bastos D.A., Dzik C., Rathkopf D., Scher H.I. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer. Oncology (Williston Park) 2014, 28:693-699.
34. Foster W.R., Car B.D., Shi H., Levesque P.C., Obermeier M.T., Gan J., et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011, 71:480-488.
35. Polkinghorn W.R., Parker J.S., Lee M.X., Kass E.M., Spratt D.E., Iaquinta P.J., et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 2013, 3:1245-1253.
36. Tombal B., Borre M., Rathenborg P., Werbrouck P., Van Poppel H., Heidenreich A., et al. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol 2014, 15:592-600.
37. Ryan C.J., Smith M.R., de Bono J.S., Molina A., Logothetis C.J., de Souza P., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013, 368:138-148.
38. Ryan C.J., Smith M.R., Fizazi K., Saad F., Mulders P.F., Sternberg C.N., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015, 16:152-160.